FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated April 16, 2019

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x             Form 40-F   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  o                          No    x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  Not applicable.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date:  April 16, 2019

 

 

GENETIC TECHNOLOGIES LIMITED

 

 

 

 

 

By:

 

/s/ Paul Viney

 

Name:

 

Paul Viney

 

Title:

 

Company Secretary

 

2

 

EXHIBIT INDEX

 

Exhibit

 

Description of Exhibit

 

 

 

99.1

 

ASX Market Announcement, April 16, 2019

 

3

Exhibit 99.1

 

ASX Market Announcement

 

16 April 2019

 

Genetic Technologies  (ASX: GTG; Nasdaq: GENE)

 

Extension of Interim CEO Contract

 

Genetic Technologies Limited (“Company”), a provider of world-leading genetic risk assessment test products announces that it has extended its contract with Dr Paul Kasian as Interim CEO until 30 June 2019, increasing his services to being a full time commitment and adjusted his remuneration accordingly. Dr Kasian will receive $196,228 per annum for his Interim CEO duties, inclusive of superannuation. These adjustments are effective as of 1 April 2019.

 

·                   Short Term Incentives — no change in structure

 

·                   Long Term Incentives — no change in structure or quantum

 

Dr Kasian continues as Chairman and his remuneration for these services is unchanged at $103,772 per annum, inclusive of superannuation, as previously announced.

 

The Board also announces that it will now embark upon a full review of the Board and Management structure of GTG, with any agreed changes to be concluded and implemented by 30 June 2019.

 

-ENDS-

 

About Genetic Technologies Limited

 

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGen plus ®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

 

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com

 

Safe Harbor Statement

 

Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.

 

Genetic Technologies Limited

60-66 Hanover Street

www.gtglabs.com

Fitzroy Victoria 3065

info@gtglabs.com

Australia

ABN 17 009 212 328

+61 3 8412 7000